Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00338260
Status:
COMPLETED
Last Update Posted:
2022-02-15
First Post:
2006-06-15
Brief Title:
Losartan Intervention For Endpoint Reduction in Hypertension LIFE Study 0954-133
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A Triple-Blind Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The LIFE study was conducted from 1995-2001 This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart The results showed that after an average treatment time of 48 years treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke The main study results were published in Dahlof et al Lancet 2002359995-1003
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006_502 | None | None | None |